FDA approves innovative drug for menopausal hot flashes.
The FDA has approved Veozah, an oral medication that targets the neural activity causing hot flashes during menopause. It is the first neurokinin 3 receptor antagonist approved by the FDA to treat moderate to severe hot flashes from menopause. Veozah is not a hormone and is an additional safe and effective treatment option for women who cannot take hormone therapies. The most common side effects of Veozah include abdominal pain, diarrhea, insomnia, back pain, hot flush, and elevated hepatic transaminases.